Entry Point Capital, LLC Kal Vista Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 3,530 shares of KALV stock, worth $40,100. This represents 0.06% of its overall portfolio holdings.
Number of Shares
3,530
Previous 7,784
54.65%
Holding current value
$40,100
Previous $92.3 Million
54.96%
% of portfolio
0.06%
Previous 0.08%
Shares
2 transactions
Others Institutions Holding KALV
# of Institutions
122Shares Held
47.7MCall Options Held
71.8KPut Options Held
26.3K-
Vr Adviser, LLC New York, NY6.25MShares$71 Million8.08% of portfolio
-
Tang Capital Management LLC San Diego, CA4.22MShares$47.9 Million6.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$47.6 Million2.06% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$41.9 Million2.56% of portfolio
-
Capital World Investors Los Angeles, CA3.23MShares$36.7 Million0.01% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $279M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...